Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.

• Status: Completed
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine intratumoral concentration of kinase inhibitors upon 2 weeks of treatment in tumor tissue of patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: VU University Medical Center
• Treatments: Dasatinib; Erlotinib Hydrochloride; Everolimus; Lapatinib; Sorafenib; Sunitinib; Vemurafenib

Criteria

Inclusion Criteria:

• Advanced solid malignancy

• minimum age 18 years

• indication for palliative treatment

• measurable disease with at least one lesion accessable for biopsy

Exclusion Criteria:

• Cardiovascular conditions including congestive heartfailure NYHA class >2

• recent myocardial infarction or uncontrolled coronary artery disease

• cardiac arrhythmias requiring anti-arrhythmic therapy

• uncontrolled hypertension

• uncontrolled infections

• serious non-healing wound, ulcer or bone fracture

• pregnant or breast feeding